GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (OTCPK:ATHJF) » Definitions » Price-to-Owner-Earnings

Percheron Therapeutics (Percheron Therapeutics) Price-to-Owner-Earnings : (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Percheron Therapeutics Price-to-Owner-Earnings?

As of today (2024-04-28), Percheron Therapeutics's share price is $0.01. Percheron Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Percheron Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Percheron Therapeutics was 29.40. The lowest was 7.60. And the median was 17.15.


ATHJF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), Percheron Therapeutics's share price is $0.01. Percheron Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01. Therefore, Percheron Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-28), Percheron Therapeutics's share price is $0.01. Percheron Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.01. Therefore, Percheron Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 13 years, Percheron Therapeutics's highest PE Ratio without NRI was 29.40. The lowest was 0.00. And the median was 17.15.


Percheron Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Percheron Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Price-to-Owner-Earnings Chart

Percheron Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Percheron Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Percheron Therapeutics's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's Price-to-Owner-Earnings falls into.



Percheron Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Percheron Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.01/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Percheron Therapeutics  (OTCPK:ATHJF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Percheron Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Percheron Therapeutics (Percheron Therapeutics) Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, Toorak, VIC, AUS, 3142
Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.